New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

21

AstraZeneca’s Hematology Cornerstone is “Completely Replacing” Previous Standards

When AstraZeneca presented positive updated results from the Phase III ASCEND study of CALQUENCE (acalabrutinib), it marked an important milestone for the company as the jewel in the crown of what management hopes will become a significant hematology portfolio. That study was significant for patients, too, because it represented a landmark 36 months of follow-up in chronic lymphocytic leukemia (CLL), which is considered an incurable disease.

22

Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine

Pfizer Inc. and BioNTech SE said on Jan. 25 they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

23

Rhode Island, in reversal, to settle opioid claims against U.S. drug distributors

Rhode Island on Jan. 25 reversed course and threw the state’s support behind a $21 billion nationwide settlement it originally declined to back resolving lawsuits alleging that three large drug distributors fueled the deadly U.S. opioid epidemic.

26

COVID-19 Brief: Omicron Mutating, Lasting Longer and Killing Faster

Two cases of a subvariant of the Omicron variant were identified in Washington state. Two cases were also identified in Houston.

30

Evoke continues to build creative powerhouse in North America with integration of Evoke Giant

Evoke, a leading global health and wellness agency, announced the integration with San Francisco-based Evoke Giant to build a seamless North American client partner. The integration formally merges the two agencies while retaining the ability to service clients independently across the United States.